Kailera Reports Third Quarter 2026 Results

The clinical-stage obesity biotech posted a net loss of $95.7 million and advanced several weight-loss programs through 2026.

Updated on Nov. 4, 2026 in Weight Loss

Isometric editorial illustration of an amber vial and injector pen on a slate surface before stacked clean-room modules in oxblood, teal, and cream. — Kailera Therapeutics reported a $95.7 million net loss for the third quarter of 2026 while its obesity drug trials remained fully enrolled. AI Illustration. Upload story photo >

Live Poll

Would you trust a new obesity drug if its price was high?

Kailera Therapeutics, a clinical-stage biotechnology company focused on obesity, reported third quarter 2026 financial results on November 4, 2026. The company ended the quarter with $1,037.6 million in cash, cash equivalents and marketable securities.

Why it matters

The results show a company spending heavily on late-stage obesity trials, with its ribupatide injection Phase 2b high-dose trial and KaiNETIC global Phase 3 program both fully enrolled. Progress on these programs will shape the company's ability to bring new weight-loss treatments to U.S. patients.

The company reported a net loss of $95.7 million for the quarter, up from $39.6 million a year earlier, with R&D spending of $84.7 million. Clinical readouts remain unresolved, with Phase 2b data for ribupatide injection expected in mid-2027 and global Phase 3 obesity data expected in mid-2028.

The players

Kailera Therapeutics

Kailera Therapeutics is a clinical-stage biotechnology company based in Waltham, Massachusetts, focused on developing treatments for obesity.

The details

Kailera said its ribupatide injection Phase 2b high-dose trial and its KaiNETIC global Phase 3 obesity program are both fully enrolled, and its safiglipron global Phase 2 trial is also fully enrolled. The company completed an End-of-Phase 2 meeting with the U.S. FDA for ribupatide oral and has an active Investigational New Drug application for KAI-4729 with the agency.

September 30, 2026: Quarter ended for the reported financial results.
November 4, 2026: Kailera reported third quarter 2026 financial results.
First half of 2027: Global Phase 3 obesity program for ribupatide oral expected to begin.
Mid-2027: Phase 2b data for ribupatide injection and Phase 2 data for safiglipron anticipated.
Mid-2028: Global Phase 3 obesity data for ribupatide injection anticipated.

Market Context

Kailera's sequence of Phase 2 completion, an End-of-Phase 2 FDA meeting, and launch of a 5,000-participant Phase 3 program follows the standard FDA pathway that obesity developers have used for recent weight-loss drugs. The company's timeline places its first large-scale efficacy readouts in mid-2028.

Patients with obesity may see new injectable and oral treatment options reach late-stage trials over the next several years. Any eventual approval would depend on Phase 3 results expected in 2028, so current patients will not see changes to available treatments from this report.

The takeaway

Investors and patients watching obesity drugs should note that Kailera's major efficacy readouts are still about two years away, and the company's $1 billion cash position will fund that work. Clinical data, not quarterly losses, will determine the drugs' eventual value.

What happens next

Kailera expects to start a global Phase 3 obesity program for ribupatide oral in the first half of 2027, with Phase 2b data for ribupatide injection due in mid-2027.